Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?

被引:29
|
作者
Kulozik, Felix [1 ]
Hasslacher, Christoph [1 ]
机构
[1] Diabet Inst Heidelberg, Landhausstr 25, D-69115 Heidelberg, Germany
关键词
diabetic nephropathy; renal insufficiency; insulin requirement; human insulin; insulin analogues; insulin glargin; insulin detemir; insulin lispro; insulin aspart;
D O I
10.1177/2042018813501188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: In diabetic nephropathy the decline of renal function causes modifications of the insulin and carbohydrate metabolism resulting in changed insulin requirements. The aim of the present study was to identify potential differences in the requirements of human insulin and various insulin analogues in patients with type 1 diabetes mellitus and renal dysfunction. Methods: The insulin requirements of 346 patients with type 1 diabetes mellitus under everyday life circumstances were assessed in an observational study. Simultaneously, laboratory parameters were measured and the estimated glomerular filtration rate (eGFR) was calculated using the formula by Cockcroft-Gault. Medical history and concomitant medication were recorded. The insulin requirements of long-and short-acting insulin were tested for a relationship with the eGFR and laboratory parameters. Results: The dosage of long-acting human insulin did not show any relation to eGFR. In contrast, a strong positive relation between dosage and renal function was found for insulin glargine and insulin detemir. After classification according to renal function, the insulin dosage at eGFR less than 60 ml/min was 29.7% lower in glargine-treated and 27.3% lower in detemir-treated patients compared with eGFR greater than 90 ml/min. Considering the whole range of eGFR, short-acting human insulin did not show a relation with renal function. Only after classification according to renal function was a dose reduction found for human insulin at eGFR less than 60 ml/min. In contrast, requirements of insulin lispro were significantly related to eGFR over the whole range of eGFR. At eGFR less than 60 ml/min the insulin dosage was 32.6% lower than at eGFR greater than 90 ml/min. The requirements of insulin aspart did not show any association with the eGFR. Conclusions: Patients with type 1 diabetes mellitus show different insulin requirements according to the renal function depending on the applied insulin. This finding is essential for the adjustment of insulin therapy in patients with diabetic nephropathy to achieve balanced glycemic control. To determine the underlying mechanisms, further studies on the pharmacokinetics and pharmacodynamics of the different insulins in patients with diabetic nephropathy are needed.
引用
收藏
页码:113 / 121
页数:9
相关论文
共 50 条
  • [31] The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes
    Mike A. Baxter
    Acta Diabetologica, 2008, 45
  • [32] Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus
    Vignati, L
    Anderson, JH
    Iversen, PW
    CLINICAL THERAPEUTICS, 1997, 19 (06) : 1408 - 1421
  • [33] Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen
    Gundgaard, Jens
    Christensen, Torsten E.
    Thomsen, Trine Lyager
    PRIMARY CARE DIABETES, 2010, 4 (03) : 165 - 172
  • [34] Human insulin versus porcine insulin in rhesus monkeys with diabetes mellitus
    Jin, Xi
    Zeng, Li
    Zhang, Shuang
    He, Sirong
    Ren, Yan
    Chen, Younan
    Wei, Lingling
    Wang, Li
    Li, Hongxia
    Cheng, Jingqiu
    Lu, Yanrong
    JOURNAL OF MEDICAL PRIMATOLOGY, 2013, 42 (01) : 1 - 9
  • [35] INSULIN ANALOGUES FOR TYPE 1 DIABETES IN CHILDREN AND ADOLESCENTS
    Galli-Tsinopoulou, A.
    Stergidou, D.
    DRUGS OF TODAY, 2012, 48 (12) : 795 - 809
  • [36] Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
    Mannucci, E.
    Monami, M.
    Marchionni, N.
    DIABETES OBESITY & METABOLISM, 2009, 11 (01): : 53 - 59
  • [37] Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: Impact on efficacy and safety
    Rolla, Arturo
    AMERICAN JOURNAL OF MEDICINE, 2008, 121 (06): : 9 - 19
  • [38] Health economic comparisons between insulin glargine and insulin detemir in patients with type 1 diabetes on intensified insulin therapy: a systematic review
    Hagenmeyer, E. -G.
    Koltermann, K. C.
    Dippel, F. -W.
    Schaedlich, P. K.
    DIABETOLOGIE UND STOFFWECHSEL, 2011, 6 (06) : 377 - 384
  • [39] Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness
    Radermecker, RP
    Scheen, AJ
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2004, 20 (03) : 178 - 188
  • [40] Insulin treatment of type 2 diabetes: Considerations when converting from human insulin to insulin analogs
    Griffin, Stacy
    ANNALS OF MEDICINE, 2013, 45 (02) : 129 - 140